期刊文献+

沙利度胺治疗强直性脊柱炎的临床疗效及其对炎症因子表达水平的影响 被引量:9

Clinical efficacy of thalidomide in the treatment of ankylosing spondylitis and its effect on inflammatory factor expression
下载PDF
导出
摘要 目的观察沙利度胺治疗强直性脊柱炎(AS)的临床疗效及其对炎症因子表达水平的影响。方法将80例活动期AS患者按随机数字表法分为观察组和对照组,对照组给予常规药物治疗,观察组在此基础上给予沙利度胺,起始剂量100mg/d,1周后150~200mg/d,疗程半年。观察2组患者治疗前后活动性指数、功能性指数、疼痛水平、晨僵时间、指地距、Schober实验、扩胸度、枕壁距、15m步行时间、肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-6、IL-23水平。结果观察组患者治疗后活动性指数、功能性指数、疼痛水平(全身痛、脊柱痛)、晨僵时间均显著低于对照组,差异有统计学意义(t=7.751,t=5.171,t=4.939,t=3.508,t=2.368,P〈0.01)。观察组患者Schober实验、扩胸度均显著高于对照组,差异有统计学意义(t=3.348,t=2.219,P〈0.01),指地距、枕壁距、15m步行时间显著低于对照组,差异有统计学意义(t=2.816,t=4.824,t=3.864,P〈0.01)。观察组患者治疗后TNF-α、IL-6、IL-23水平显著低于对照组,差异有统计学意义(t=7.951,t=5.253,t=4.044,P〈0.01)。结论沙利度胺通过改善患者炎症因子水平而减轻AS临床症状,具有良好疗效。 Objective To observe the clinical efficacy of thalidomide in the treatment of ankylosing spondylitis(AS)and its effect on the expression of inflammatory factor level.Methods Eighty patients with active ankylosing spondylitis were randomly divided into observation group and control group,40 patients in each group.The control group was given routine drug treatment,and observation group were given thalidomide on the basis of basic treatment(initial dose of 100mg/d,a week after 150-200mg/d,treatment course for a half year).The BASDAI,BASFI,pain level,time of morning stiffness,finger to floor distance,Schober test,chest expansion,the pillow wall distance,15 m walking time,TNF-α,IL-6and IL-23 level were compared between two groups.Results After treatment,the BASDAI,BASFI,pain level,time of morning stiffness in patients of observation group were significantly lower than those of the control group(t=7.751,t=5.171,t=4.939,t=3.508,t=2.368,P0.01).The Schober test,the chest wall distance and 15 mwalking time in observation group were significantly lower than those in the control group(P0.01).The levels of IL-6,IL-23 and TNF-αin the observation group were significantly lower than those in the control group(t=7.951,t=5.253,t=4.044,P0.01).ConclusionThalidomide can relieve the clinical symptoms of AS by reducing the level of inflammatory factors of patients.It has good curative effect.
出处 《山西医药杂志》 CAS 2016年第3期247-249,共3页 Shanxi Medical Journal
基金 江苏省自然科学基金(BK20157486/8)
关键词 脊柱炎 强直性 沙利度胺 炎症介导素类 Spondylitis ankylosing Thalidomide Inflammation mediators
  • 相关文献

参考文献12

  • 1Smolen JS,Braun J,Dougados M,et al.Treating spondyloarthritis,including ankylosing spondylitis and psoriatic arthritis,to target:recommendations of an international task force[J].Ann Rheum Dis,2014,73(1):6-16.
  • 2Doherty T,Lee J,Sandhu V.The introduction of ankylosing spondylitis annual review clinics at a London teaching hospital[J].Ann Rheum Dis,2013,71(Suppl 3):690.
  • 3Klausen SM,Parle J.Are we going to stand by and let these children come into the world?the impact of the thalidomide disaster in south africa,1960-1977[J].J South Afric Stud,2015,41(4):735-752.
  • 4Kawai T,Watanabe N,Yokoyama M,et al.Thalidomide attenuates excessive inflammation without interrupting lipopolysaccharide-driven inflammatory cytokine production in chronic granulomatous disease[J].Clin Immunol,2013,147(2):122-128.
  • 5Deng X,Zhang J,Zhang J,et al.Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept[J].Rheumatol Int,2013,33(6):1409-1413.
  • 6Sve?lv BEG,T?ng MS,Klingberg E,et al.PW306by following recommended guidelines by American Society of Echocardiography,diastolic dysfunction is observed in twelve percent of the patients with ankylosing spondylitis[J].Global Heart,2014,1(9):e319.
  • 7Carbo MJ,Arends S,Brouwer E,et al.SAT0257 NSAID use in relation to disease activity in patients with ankylosing spondylitis treated with and without TNF-αblocking therapy in daily clinical practice[J].Ann Rheum Dis,2015,74(Suppl 2):751.
  • 8Sveaas SH,Berg IJ,Provan SA,et al.Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis:a cross-sectional comparative study[J].Scand J Rheumatol,2015,44(2):118-124.
  • 9Dhir V,Srivastava R,Aggarwal A.Circulating levels of soluble receptor activator of NF-κB ligand and matrix metalloproteinase 3(and their antagonists)in Asian Indian patients with ankylosing spondylitis[J].Int J Rheumatol,2013,2013(1):814350.
  • 10Piura B,Medina L,Rabinovich A,et al.Thalidomide distinctly affected TNF-α,IL-6and MMP secretion by an ovarian cancer cell line(SKOV-3)and primary ovarian cancer cells[J].Eur Cytokine Netw,2013,24(3):122-129.

二级参考文献27

共引文献14

同被引文献63

引证文献9

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部